Arthrosi Therapeutics
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Quick Facts
Arthrosi Therapeutics: Series E Funding Round
Arthrosi Therapeutics has successfully raised $153M in Series E funding, reaching a valuation of $800M.
Company Overview
Developing next-generation gout treatment drug for chronic conditions
Funding Details
The Series E round was led by New Enterprise Associates, with participation from RA Capital.
Company Information
- Headquarters: San Diego, CA
- Founded: 2019
- Employees: 120+
- Category: Biotech
Investment
Arthrosi Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- New Enterprise Associates: Verified investor in Series E
- RA Capital: Verified investor in Series E
Key Investors
About the Author
Related Company Reports
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
NeuralTech Raises $100M Growth to Transform Biotech
NeuralTech has secured $100M Growth in funding to accelerate growth and innovation. Leading AI-powered analytics platform transforming data into actionable business insights...